BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20979663)

  • 1. Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia.
    Beesley AH; Rampellini JL; Palmer ML; Heng JY; Samuels AL; Firth MJ; Ford J; Kees UR
    Mol Cancer; 2010 Oct; 9():284. PubMed ID: 20979663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
    Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential network analysis and protein-protein interaction study reveals active protein modules in glucocorticoid resistance for infant acute lymphoblastic leukemia.
    Mousavian Z; Nowzari-Dalini A; Rahmatallah Y; Masoudi-Nejad A
    Mol Med; 2019 Aug; 25(1):36. PubMed ID: 31370801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Spijkers-Hagelstein JA; Schneider P; Hulleman E; de Boer J; Williams O; Pieters R; Stam RW
    Leukemia; 2012 Jun; 26(6):1255-65. PubMed ID: 22282267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101.
    Spijkers-Hagelstein JA; Schneider P; Pinhanços SM; Garrido Castro P; Pieters R; Stam RW
    Eur J Cancer; 2014 Jun; 50(9):1665-74. PubMed ID: 24703900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
    Mousavian Z; Nowzari-Dalini A; Stam RW; Rahmatallah Y; Masoudi-Nejad A
    Cell Oncol (Dordr); 2017 Feb; 40(1):33-45. PubMed ID: 27798768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.
    Spijkers-Hagelstein JA; Pinhanços SS; Schneider P; Pieters R; Stam RW
    Leukemia; 2014 Apr; 28(4):761-9. PubMed ID: 23958920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Spijkers-Hagelstein JA; Mimoso Pinhanços S; Schneider P; Pieters R; Stam RW
    Leukemia; 2013 Apr; 27(5):1063-71. PubMed ID: 23334362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Meijerink JP; Ebus ME; Peters GJ; Noordhuis P; Janka-Schaub GE; Armstrong SA; Korsmeyer SJ; Pieters R
    Blood; 2003 Feb; 101(4):1270-6. PubMed ID: 12406912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221.
    Kotani A; Ha D; Hsieh J; Rao PK; Schotte D; den Boer ML; Armstrong SA; Lodish HF
    Blood; 2009 Nov; 114(19):4169-78. PubMed ID: 19749093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
    Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
    Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
    Tamai M; Furuichi Y; Kasai S; Ando N; Harama D; Goi K; Inukai T; Kagami K; Abe M; Ichikawa H; Sugita K
    Leuk Res; 2017 Oct; 61():68-76. PubMed ID: 28917156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
    Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
    Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
    Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia.
    Mata JF; Scrideli CA; Queiroz RP; Mori BO; Emerenciano M; Pombo-de-Oliveira MS; Tone LG
    Braz J Med Biol Res; 2006 Nov; 39(11):1417-23. PubMed ID: 17146554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.
    van der Linden MH; Willekes M; van Roon E; Seslija L; Schneider P; Pieters R; Stam RW
    Cell Cycle; 2014; 13(5):834-44. PubMed ID: 24736461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
    Stumpel DJ; Schneider P; van Roon EH; Boer JM; de Lorenzo P; Valsecchi MG; de Menezes RX; Pieters R; Stam RW
    Blood; 2009 Dec; 114(27):5490-8. PubMed ID: 19855078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
    de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
    EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-kappaB activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemia.
    Tracey L; Streck CJ; Du Z; Williams RF; Pfeffer LM; Nathwani AC; Davidoff AM
    Leukemia; 2010 Apr; 24(4):806-12. PubMed ID: 20130599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based RT-PCR methods for the detection of the 8 most common MLL aberrations in acute leukemias.
    Burmeister T; Meyer C; Gröger D; Hofmann J; Marschalek R
    Leuk Res; 2015 Feb; 39(2):242-7. PubMed ID: 25510485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.